Zoetis

Overview
Activities
Financials
News

Zoetis Inc. (NYSE: ZTS) is the world's leading animal health company, focused on developing and manufacturing medicines, vaccines, diagnostic products and other technologies for companion and livestock animals.

Zoetis offers a diverse portfolio of products across eight core animal species - cattle, swine, poultry, fish, sheep, dogs, cats and horses. Its product lines include vaccines, parasiticides, anti-infectives, medicated feed additives, and other pharmaceuticals. The company also provides diagnostic instruments and genetic tests for veterinary use. Key products include Apoquel and Cytopoint for dermatology, Simparica Trio for parasites, and Librela and Solensia for osteoarthritis pain in pets.

In 2023, Zoetis reported revenue of USD 8.5 billion, a 6% increase over the previous year. The company has a global presence, with products sold in over 100 countries. Zoetis continues to invest heavily in research and development, spending USD 508 million on R&D in 2021. Recent innovations include the launch of AI-powered diagnostic tools and new vaccines for livestock. The company is also expanding its capabilities in areas like telemedicine and precision animal health to drive future growth in the evolving animal healthcare market.

HQ Location:
10 Sylvan Way Parsippany NJ USA
Founded year:
2014
Employees:
10,000+
InsurTech: Personal Lines
InsurTech: Personal Lines
Animal Therapeutics
Animal Therapeutics
Livestock Biotech
Livestock Biotech
Loading...

EDGE Insights

arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.